VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication

World Journal of Gastroenterology

Volumn 11, Issue 41, 2005, Pages 6429-6432

  Yi, Jun ^a   Gong, Wei Dong ^b   Wang, Ling ^a   Ling, Rui ^a   Chen, Jiang Hao ^a   Yun, Jun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Dominant negative mutant; Hepatitis B virus; VP22

Indexed keywords

CORE PROTEIN; HEPATITIS B SURFACE ANTIGEN; HYBRID PROTEIN; MUTANT PROTEIN; PROTEIN VP22; VIRUS DNA;

ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ACTIVITY; CELL METABOLISM; COLORIMETRY; CONTROLLED STUDY; DRUG MECHANISM; FLUORESCENCE ANALYSIS; GENE THERAPY; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LIVER CELL; MOLECULAR CLONING; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 31344439005     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i41.6429     Document Type: Article

References (26)

1. Fleming J. Current treatments for hepatitis. J Infus Nurs 2002; 25: 379-382
2. elSaadany S, Tepper M, Mao Y, Semenciw R, Giulivi A. An epidemiologic study of hepatocellular carcinoma in Canada. Can J Public Health 2002; 93: 443-446
3. Mazumdar TN. Management of chronic hepatitis B infection: an update. J Indian Med Assoc 2001; 99: 306-308, 310
4. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56: 651-693
5. Tang ZY. Hepatocellular carcinoma - cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
6. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-1430
7. Manns MP. Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis 2002; 22 Suppl 1: 7-13
8. Shindo M, Hamada K, Koya S, Sokawa Y, Okuno T. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Am J Gastroenterol 1999; 94: 2237-2245
9. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat 2002; 9: 393-399
10. Wolters LM, Hansen BE, Niesters HG, de Man RA. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. Eur J Gastroenterol Hepatol 2002; 14: 1007-1011
11. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300-306
12. Chiou HC, Lucas MA, Coffin CC, Banaszczyk MG, Ill CR, Lollo CP. Gene therapy strategies for the treatment of chronic viral hepatitis. Expert Opin Biol Ther 2001; 1: 629-639
13. von Weizsacker F, Kock J, Wieland S, Offensperger WB, Blum HE. Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis. Hepatology 1999; 30: 308-315
14. von Weizsacker F, Wieland S, Kock J, Offensperger WB, Offensperger S, Moradpour D, Blum HE. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 1997; 26: 251-255
15. Scaglioni P, Melegari M, Takahashi M, Chowdhury JR, Wands J. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996; 24: 1010-1017
16. von Weizsacker F, Wieland S, Blum HE. Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein Hepatology 1996; 24: 294-299
17. Scaglioni PP, Melegari M, Wands JR. Characterization of hepatitis B virus core mutants that inhibit viral replication. Virology 1994; 205: 112-120
18. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-233
19. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 1987; 84: 1005-1009
20. Acs G, Sells MA, Purcell RH, Price P, Engle R, Shapiro M, Popper H. Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc Natl Acad Sci U S A 1987; 84: 4641-4644
21. Sells MA, Zelent AZ, Shvartsman M, Acs G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol 1988; 62: 2836-2844
22. Trono D, Feinberg MB, Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989; 59: 113-120
23. Malim MH, Freimuth WW, Liu J, Boyle TJ, Lyerly HK, Cullen BR, Nabel GJ. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 1992; 176: 1197-1201
24. Elliott G, O'Hare P. Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther 1999; 6: 149-151
25. Aints A, Guven H, Gahrton G, Smith CI, Dilber MS. Mapping of herpes simplex virus-1 VP22 functional domains for inter-and subcellular protein targeting. Gene Ther 2001; 8: 1051-1056
26. Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 2000; 21: 45-48